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ABSTRACT 
 
Premna integrifolia L. belongs to family Verbenaceae and it is believed to prevent cardiovascular 
disease as per Ayurveda. In order to evaluate the cardiac biomarkers and treatment efficacy of 
hydroalcoholic extract (HAE) of root bark in atherosclerosis. Sixty Wistar rats were divided into six 
groups and ten animals in each group. Rats fed with high fat diet and various concentrations of 
HAE treatment were studied and standard drug, atorvastatin was compared with HAE. This extract 
showed a significant action against atherosclerosis in a dose dependent manner which was studied 
in terms of lactate dehydrogenase activity, HMG-CoA/Mevalonate ratio, collagen content in aorta, 
levels of transaminases, calcium and other marker enzymes indirectly involved in the cardio 
protection. Alteration in collagen deposition in aorta of histopathological evaluation was noticed in 
treated animals. Anti-atherosclerotic activity of HAE of P. integrifolia was due to its modulatory 
activity on cholesterol metabolism and our results contribute towards validation of the traditional 
use of P. integrifolia in high fat diet induced atherosclerosis.  
Short Research Article 
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1. INTRODUCTION 
 
Hyperlipidemia is one of the important factors 
associated with atherosclerosis, hypertension, 
smoking, diabetes mellitus etc. Atherosclerosis is 
a multi-factorial disease induced by various 
factors on suitable genetic backgrounds. It is 
characterized by the vascular areas containing 
mononuclear proliferation of smooth muscle cells 
resulting in thickening and hardening of the 
arterial walls [1]. The HMG-CoA reductase 
inhibitors play an important role in the reduction 
of lipid and lipoprotein levels. The most effective 
and widely used commercially available drugs for 
the treatment of hyperlipidemia are statins. Their 
primary site of action is in liver where they inhibit 
HMG-CoA reductase, the metabolic pathway that 
produces cholesterol and isoprenoids [2]. 
Impaired perfusion from decreased cardiac 
output may be associated with marked elevations 
in serum aminotransferases. Bridging fibrosis or 
cardiac cirrhosis can result from prolonged 
hemodynamic abnormalities, resulting in an 
impaired hepatic function with impaired 
coagulation, and alteration in the metabolism of 
several cardiovascular drugs, which can lead to 
unwanted toxicity [3]. Today, the Indian Systems 
of Medicine are not only complementary but also 
competitive in the treatment of various diseases. 
Herbs and herbal based compounds have 
always been an important source of medicines 
for various diseases and have received 
considerable attention in recent years due to 
their diverse pharmacological actions. Plants 
have a significant role in maintaining human 
health and improving the quality of life. Premna 
integrifolia is a medicinal plant and popularly 
known as “Agnimantha” in Ayurvedic systems of 
medicine and this plant root is commonly used in 
Dasamula drug preparation of Ayurveda. Hence 
the present study is focused on identification of 
liver abnormalities and complex relationship 
between cardiac and hepatic function in 
atherosclerosis. The hydroalcoholic extract of 
root bark of P. integrifolia may gain knowledge 
on hepatic biomarkers which further improve our 
understanding on disease process with less or 
no side effects in rats fed with high fat diet. 
 
2. MATERIALS AND METHODS 
 
2.1 Preparation of the Plant Extract 
  
The root bark was procured, authenticated and 
voucher specimen (00641/2014) was deposited 
in the Botany Department, Captain Srinivasa 
Murthi Regional Ayurveda Drug Development 
Institute, Chennai, India. The bark was shade 
dried and coarsely powdered. The powder was 
defatted with petroleum ether (60-80°C) and then 
extracted with hydro alcohol (60:40 v/v) in a 
Soxhlet extractor and dried under vacuum. The 
percentage yield of HAE was 7.61% w/w and this 
extract was suspended in 0.5% sodium carboxyl 
methyl cellulose (SCMC) for the pharmacological 
screening.  
 
2.2 Induction of Atherosclerosis 
 
Experiment was conducted on 60 (30M+30F) 
Wistar rats of 6-8 weeks of age and purchased 
from King’s Institute of Preventive Medicine, 
Guindy, India. Rats were randomly divided in to 6 
groups and 10 animals (5M+5F) in each group, 
maintained in individual cage under controlled 
temperature, humidity and illumination conditions 
with water and diet ad libitum. High fat                 
diet consisted of 2.0 g of cholesterol, 8.0 g of 
saturated fat and 0.1 g of calcium       
(BYCALVIT-500 (Biochem Pharmaceutical 
Industries Ltd., Mumbai, India) mixed thoroughly 
with 90 g of powdered standard commercial 
pellet diet along with weekly challenge of oral 
Vitamin D3 (3,00,000 IU) through per oral route 
[4]. Extract, vehicle and standard drug were 
administered daily through intra gastric route for 
30 days. 
 
2.3 Experimental Protocol for 
Atherosclerotic Study 
 
Rats fed with 
 
Group-I   : Standard pellet diet (n=10)  
Group-II  : High fat diet (n=10)  
Group-III : High fat diet+100 mg/kg.b.wt. of 
hydroalcoholic extract (n=10)  
Group-IV : High fat diet+200 mg/kg.b.wt. of 
hydroalcoholic extract (n=10) 
Group-V  : High fat diet +500 mg/kg.b.wt. of 
hydroalcoholic extract (n=10)  
Group-VI : High fat diet +10 mg/kg.b.wt. of 
Atorvastatin (n=10)  
 
2.4 Biochemical Analysis 
 
At the end of experimental period, 4 mL of blood 
was collected in a vacutainer from retro-orbital 
plexus under mild ether anesthesia. Serum was 
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separated by centrifugation (Remi C-24) at 4°C 
for 10 minutes at 3000 rpm. Euthanasia was 
performed with carbon dioxide and tissues of 
liver and aorta were removed. Liver was used for 
biochemical assays and aorta was preserved in 
10% formalin for histopathology study of collagen 
deposition in aorta with picrosirius red staining 
[5]. The serum biochemical parameters such as 
aspartate amino transferase (AST), alanine 
amino transferase (ALT), alkaline phosphatase 
(ALP), lactate dehydrogenase (LDH) and 
creatine phosphokinase (CPK), bilirubin total and 
calcium (arsenazo, III-colorimetric) were assayed 
by clinical chemistry fully autoanalyser (XL-640; 
Transasia) using kits of system pack from ERBA. 
Instrument was calibrated with XL-multical (Erba 
XL SysPack-Level 1-14441) and quality control 
(Biorad) was run before started the analysis.  
Liver biochemical parameters AST & ALT [6], 
acid phosphatase (ACP) & ALP [7], LDH [8], 
HMG-CoA/mevalonate ratio [9], collagen [10] and 
total protein [11] were estimated by UV-visible 
spectrophotometer (Perkin-Elmer XE2-201) by 
standard procedures. 
 
2.5 Data Analysis  
 
Statistical analysis was carried out using Graph 
pad prism 5.0. All the values were expressed as   
mean ± SD (n=10). Groups of data were 
compared with the analysis of variance (ANOVA) 
followed by Dunnett’s test for multiple 
comparison. Values were considered statistically 
significant when P<0.05. 
 
3. RESULTS 
 
The serum ALT activity was increased in Group-
II (p<0.001) when compared to Group-I. The 
decreased activity was observed in Group-V 
(p<0.01) when compared to Group-II. The activity 
of AST was increased in Group-II and in Group-
III when compared to Group-I. The AST activity 
was decreased in Group-IV (p<0.05) and in 
Group-V (p<0.001) compared to Group-II. The 
activity of ALP was increase in Group-II (p<0.05) 
when compared to Group-I (Table 1). The serum 
LDH activity was increased in Group-II 
(p<0.0001), Group-III (p<0.0001) and Group-IV 
(p<0.01) compared to Group-I. The activity was 
decreased in Group-III (p<0.05), Group-IV 
(p<0.0001), Group-V (p<0.0001) and Group-VI 
(p<0.0001) when compared to Group II. The LDH 
activity was decreased in Group-V (p<0.0001) 
and in Group-VI (p<0.01) when compared to 
Group-III. The CPK activity was increased in 
Group-II (p<0.001) compared to Group-I and 
decreased in Group-IV (p<0.01), Group-V 
(p<0.001) and Group-VI (p<0.05) when 
compared to Group-II. The collagen content in 
liver was significantly increased in Group-II 
(p<0.0001) and III (p<0.001) when compared to 
Group-I. The level was significantly decreased in 
Group-IV (p<0.05), V (p<0.001) and VI (p<0.01) 
when compared to Group-II. A significant 
reduction was noticed in Group-V (p<0.01) and 
VI (p<0.05) when compared to Group-III. A 
significant reduction in calcium content of Group-
III (p<0.05), IV & V (p<0.01) when compared to 
Group-II (Table 2). 
 
The level of bilirubin total was elevated by 35% in 
Group-II compared to Group-I. 22.7% decreased 
in Group-III, 25.58% in Group-IV, 28.57% in 
Group-V and 31.71% in Group-VI when 
compared to Group-II (Fig. 1). The level of 
calcium was significantly increased in Group-II 
(p<0.0001) and III (p<0.05) when compared to 
Group-I. The level of calcium was significantly 
decreased in Group-IV (p<0.05) and V (p<0.01) 
when compared to Group-II (Fig. 2). The activity 
of liver ALT was significantly increased in Group-
II (p<0.001) compared to Group-I. Group-V 
 
Table 1. Assay of serum Alanine transaminase, Aspartate transaminase  
and Alkaline phosphatase 
 
Group Alanine transaminase 
(mg pyruvate liberated/ 
mg protein at 37°C for 
30 minutes) 
Aspartate transaminase 
(mg pyruvate liberated/ mg 
protein at 37°C for 
60 minutes) 
Alkaline phosphatase 
(µg phenol  liberated/ 
mg protein at 37°C for 
15 minutes) 
Group-I 0.584±0.086 0.389±0.117 0.482±0.082 
Group-II 0.944±0.260a*** 0.524±0.046a* 0.687±0.147a* 
Group-III 0.798±0.167 0.415±0.072a* 0.581±0.185 
Group-IV 0.728±0.166 a,b 0.398±0.088b* 0.522±0.097 
Group-V 0.649±0.134b** 0.353±0.057b*** 0.515±0.129 
Group-VI 0.719±0.162 0.421±0.089 0.544±0.091 
[Values are mean ± SD; n=10; *p<0.05; **p<0.01; ***p<0.001] 
aResults were compared with Group-I; bCompared with Group-II 
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Table 2. Assay of serum lactate dehydrogenase and creatine phosphokinase 
 
Group Lactate dehydrogenase (IU/L) Creatine phosphokinase 
(IU/L) 
Collagen 
(µg/mg protein) 
Group-I 249.90±42.46 166.50±44.4 38.83±16.25 
Group-II 539.78±89.82a**** 282.43±35.5a*** 92.51±24.67a**** 
Group-III 432.70±78.02a****; b* 231.28±58.7 82.07±26.17a**** 
Group-IV 374.20±63.54a**; b****; 188.48±85.7b** 76.52±41.40 b* 
Group-V 273.56±58.79b****; c**** 165.49±35.5b*** 38.95±22.94b***; c** 
Group-VI 309.22±61.24b****; c** 195.09±57.0b* 40.07±29.66b**; c* 
[Values are mean ± SD; n=10; *p<0.05; **p<0.01; ***p<0.001; p<0.0001] 
aResults were compared with Group-I; bCompared with Group-II; cCompared with Group-III 
 
 
Fig. 1. Estimation of bilirubin total in serum 
[Values are mean ± SD; n=10; aResults were compared with Group-I; bCompared with Group-II] 
 
 
Fig. 2. Estimation of calcium in serum 
[Values are mean ± SD; n=10; *p<0.05; **p<0.01; ****p<0.0001] 
aResults were compared with Group-I; bCompared with Group-II 
 
showed a significant decrease (p<0.01) in activity 
than Group-II. The activity of liver AST was 
significantly increased in Group-II and III 
(p<0.05) when compared to Group-I. Group-IV 
(p<0.05) and V (p<0.001) showed a significant 
decrease in AST activity when compared to 
Group-II. The activity of ALP was significantly 
high in Group-II (p<0.05) when compared to 
0
2
4
6
8
10
12
14
16
18
G-I G-II G-III G-IV G-V G -VI 
m
g/
dl
a35%
b22.7% b25.6% b28.6% b31.7%
0
2
4
6
8
10
12
14
16
18
G-I G-II G-III G-IV G-V G -VI 
m
g/
dl
a****
a* b*
b** a,b
NS
  
 
 
Chitra et al.; IJBCRR, 17(3): 1-9, 2017; Article no.IJBCRR.34232 
 
 
 
5 
 
Group-I. The activity of ALP in liver was 
decreased but no significant difference was 
found in all other groups when compared to 
Group-II (Table 3). The activity of ACP in liver 
was significantly increased in Group-II (p<0.01), 
III (p<0.05) when compared to Group-I and 
significant decrease was observed in Group-V 
(p<0.05) when compared to Group-II. The activity 
of LDH in liver was significantly increased in 
Group-II, III, IV (p<0.0001) and VI (p<0.05) when 
compared to Group-I and significant decrease 
was noticed in Group-III, IV, V and VI (p<0.0001) 
when compared to Group-II. A significant 
decrease was observed in Group-IV and VI 
(p<0.01) and V (p<0.0001) when compared to 
Group-III. HMG CoA/mevalonate ratio was 
decreased in Group-II (p<0.01) compared to 
Group-I. A significant improvement was noticed 
in Group-IV, VI (p<0.01), V (p<0.001) when 
compared with Group-II (Table 4). 
 
4. DISCUSSION 
 
Measurement of LDH activity in blood is 
considered to be a diagnostic marker for certain 
cardiovascular diseases and it is a sensitive 
measure of myocardial infarction [12]. When 
inadequate end-organ perfusion and tissue 
hypoxia is persistent or when acute shock 
develops this protecting mechanism against 
hypoxic liver damage is overwhelmed. 
Hepatocellular injury ensues, accompanied by 
sharp elevation of the serum aminotransferases, 
LDH and occasionally functional renal 
impairment. Ischemic hepatitis is usually benign 
and self-limited. Aspartate transaminase level is 
used as a diagnostic marker for myocardial 
infarction. In pathological conditions, the 
enzymes such as CPK, LDH, AST and ALT leaks 
from the necrotic heart cells to blood, which are 
important measure of cardiac injury. These 
enzymes are not specific for myocardial injury 
individually; however, evaluation of these 
enzymes together may be an indicator of 
myocardial damage [13,14]. CPK is another 
important enzyme in energy metabolism in body 
which maintains the high concentration of 
intracellular ATP through phosphorylation and it 
is considered as important index for 
atherosclerosis [15]. Higher activities of these 
enzymes in serum have been found in            
response to oxidative stress induced by high  
 
Table 3. Assay of liver Alanine transaminase, Aspartate transminase, Alkaline phosphatase 
 
Group Alanine transaminase 
(mg pyruvate liberated/ 
mg protein at 37°C for 
30 minutes) 
Aspartate transaminase 
(mg pyruvate liberated/ 
mg protein at 37°C for 
60 minutes) 
Alkaline phosphatase 
(µg phenol  liberated/ mg 
protein at37°C for 
15 minutes) 
Group-I 0.584±0.086 0.389±0.117 0.482±0.082 
Group-II 0.944±0.260a*** 0.524±0.046a* 0.687±0.147a* 
Group-III 0.798±0.167 0.415±0.072a* 0.581±0.185 
Group-IV 0.728±0.166 0.398±0.088b* 0.522±0.097 
Group-V 0.649±0.134 b** 0.353±0.057 b*** 0.515±0.129 
Group-VI 0.719±0.162 0.421±0.089 0.544±0.091 
[Values are mean ± SD; n=10; *p<0.05; **p<0.01; ***p<0.001] 
aResults were compared with Group-I; bCompared with Group-II 
 
Table 4. Assay of liver Acid phosphatase, Lactate dehydrogenase and HMG CoA/ mevalonate 
ratio 
 
Group Acid phosphatase 
(µg phenol  liberated/  mg protein 
at 37°C for 60 minutes)  
Lactate dehydrogenase 
(µmoles/mg protein) 
HMG CoA/ 
mevalonate ratio 
Group-I 0.209±0.052 85.36±12.91 1.161±0.110 
Group-II 0.408±0.076a** 808.89±103.89a**** 1.404±0.144a** 
Group-III 0.366±0.138a* 440.39±123.91a,b**** 1.204±0.105 
Group-IV 0.336±0.152 300.15±56.01a,b****; c** 1.158±0.150b** 
Group-V 0.241±0.123b* 143.42±70.97 b****; c**** 1.056±0.139b*** 
Group-VI 0.263±0.112 195.66±66.72a*;b****; c** 1.108±0.130b** 
[Values are mean ± SD; n=10; *p<0.05; **p<0.01; ***p<0.001; p<0.0001]] 
aResults were compared with Group-I; bCompared with Group-II; cCompared with Group-III 
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Group-I Group-II 
 
  
 
Group-III Group-IV 
 
  
 
Group-V Group-VI 
 
Fig. 3. Histopathology of collagen deposition in aorta 
                     Legend: 
Group-I : No collagen accumulation  
Group-II : Well defined collagen accumulation with mineralization 
Group-III    : Moderate accumulation of collagen with less demineralization 
Group-IV    : Mild collagen accumulation with marked demineralization 
Group-V 
Group-VI 
: 
: 
Mild collagen accumulation with severe demineralization  
Moderate collagen accumulation with less demineralization 
 
 
fat diet [16]. Impaired perfusion from low cardiac 
output results in cardiogenic ischemic hepatitis. 
The hall mark findings of ischemic hepatitis are 
severe jaundice with high bilirubin level and 
elevated liver function tests. Increase in LDH 
tends to be massive and ALT/LDH ratio may help 
distinguishing ischemic injury from other forms of 
acute hepatitis [17,18]. There was a significant 
restoration of these enzymes on administration 
with different concentrations of HAE of               
P. integrifolia. The activity of AST, ALT, CPK and 
LDH was inversely proportional to the 
concentration of HAE extract. Liver plays a 
central role in the absorption, distribution and 
elimination of majority of drugs. Collagen is a 
family of proteins consists of several genetically 
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different molecular species and is closely 
involved in tissue organization, function, 
differentiation and development [19]. The unique 
distribution of hydroxyl proline within the collagen 
can easily be studied [20]. Hepatic impairment 
can alter the pharmacokinetic profiles of 
cardiovascular drugs, which can lead to 
unwanted toxicity. On treatment with HAE, 
reversibility of changes was noticed when 
compared to high fat fed rats (Fig. 3). 
 
Liver function tests abnormalities were common 
in patients with chronic heart failure. Elevated 
total bilirubin remained one of the strongest 
independent predictors of poor prognosis. An 
intracellular cation has significant role in the 
regulation of normal physiology and biochemistry 
of cardiac and smooth muscles. Flavonoids, 
have been found to suppress the intracellular 
high Ca2+ ion in a dose dependent manner, as 
well as the release of pro-inflammatory mediators 
such as tumor necrosis factor-α [21]. Studies 
revealed that tannins, triterpenoids and flavonoid 
are the major phytoconstituents of P. integrifolia 
[22,23]. HAE have an essential phytoconstituents 
including flavonoid might help in the reduction of 
intracellular calcium levels in the drug treated 
groups.  
 
Elevated transaminases should be seriously 
considered in patients with cardiac disease and 
also elevation of each cholestatic liver function 
tests was significantly associated with the degree 
of tricuspid incompetence [24]. During hepatic 
impairment, the bioavailability is double and the 
total plasma clearance is halved. Marked 
decrease in liver transaminases, ACP and ALP 
levels demonstrate the cardio-protective effect of 
P. integrifolia. HAE has cadioprotective activity 
along with hepatoprotective activity which was 
evident in liver marker enzymes in extract treated 
groups. Due to the presence of flavonoid, a 
secondary metabolite in HAE could enhance the 
antioxidant defense mechanisms and prevents 
muscle cell damage. LDH is less specific than 
AST and ALT as a marker of hepatocyte injury, 
but LDH may disproportionately elevated after an 
ischemic liver injury. The activity of LDH was 
reported to be high in rats fed with high fat diet 
induced obesity [25]. The HAE might protect the 
cell by reducing the activities of these marker 
enzymes. HMG-CoA reductase activity was 
indirectly measured in terms of HMG 
CoA/Mevalonate ratio in liver tissue [9]. Inhibitors 
of HMG-CoA reductase are used to lower serum 
cholesterol levels and improve the survival of 
individuals at risk of atherosclerotic vascular 
disease [26]. Their primary site of action is in 
liver where they inhibit HMG-CoA reductase, the 
metabolic pathway that produces cholesterol and 
isoprenoids [27]. Atorvastatin treated rats 
showed a significant reduction in the ratio of 
HMG-CoA/Mevalonate which might be due to the 
inhibition of HMG-CoA reductase activity by 
HAE. The most effective and widely used drugs 
for the treatment of hyperlipidemia are the 
atorvastatin and this drug competitively inhibit 
HMG-CoA reductase enzyme in liver that 
converts HMG-CoA to mevalonate an early 
precursor for cholesterol biosynthesis. Hence this 
enzyme might competitively inhibited by the HAE 
which was evident from the lipid and lipoprotein 
status.  
 
5. CONCLUSION 
 
In conclusion, all HMG-CoA reductase inhibitor 
undergo extensive hepatic metabolism. Active 
liver disease or persistent unexplained elevations 
in serum transaminases to above 3 times the 
upper limit of normal, the use of statins is 
contraindicated as they may worsen liver function 
[28]. Therefore the cardio tonic action of the HAE 
might attribute to the phytoconstituents present in 
it. From the above findings, HAE of P. integrifolia 
modulates enzyme activity in a dose-dependent 
manner and further research is required on which 
active principle is mainly involved in the anti-
atherosclerotic activity of high fat diet-induced 
atherosclerosis.  
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